Third Pole Therapeutics

Third Pole Therapeutics is a US-based startup with a vision to revolutionize cardiopulmonary therapy. Established in 2014, the company is dedicated to developing advanced life-saving therapies for heart and lung conditions. Their novel approach involves creating a lightweight device capable of generating nitric oxide (NO) from air on-demand, aiming to eradicate the need for large compressed gas cylinders. This breakthrough has the potential to expand the usage of inhaled NO beyond acute care settings, creating new markets globally. The company recently secured a significant $32.00M Series B investment on 14 December 2022, signaling strong investor confidence in their transformative technology. The absence of disclosed investors indicates a potential strategic move to maintain confidentiality or a desire to leverage the investment as a springboard for future partnerships. Third Pole Therapeutics holds great promise in reshaping the landscape of cardiopulmonary therapy on a global scale.